ATE424379T1 - Verfahren zur herstellung von gesamt- salvianolsäure - Google Patents

Verfahren zur herstellung von gesamt- salvianolsäure

Info

Publication number
ATE424379T1
ATE424379T1 AT03732181T AT03732181T ATE424379T1 AT E424379 T1 ATE424379 T1 AT E424379T1 AT 03732181 T AT03732181 T AT 03732181T AT 03732181 T AT03732181 T AT 03732181T AT E424379 T1 ATE424379 T1 AT E424379T1
Authority
AT
Austria
Prior art keywords
acid
tanshintotalphenolic
salvianolic acid
producing total
total salvianolic
Prior art date
Application number
AT03732181T
Other languages
English (en)
Inventor
Feng Wei
Hongshui Yue
Dekun Li
Jiangxiao Sun
Zhengliang Ye
Xu Li
Original Assignee
Tianjin Tasly Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Tasly Pharmaceutical filed Critical Tianjin Tasly Pharmaceutical
Application granted granted Critical
Publication of ATE424379T1 publication Critical patent/ATE424379T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03732181T 2002-05-23 2003-05-21 Verfahren zur herstellung von gesamt- salvianolsäure ATE424379T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB021179239A CN1202103C (zh) 2002-05-23 2002-05-23 丹参总酚酸的制备方法

Publications (1)

Publication Number Publication Date
ATE424379T1 true ATE424379T1 (de) 2009-03-15

Family

ID=29426731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03732181T ATE424379T1 (de) 2002-05-23 2003-05-21 Verfahren zur herstellung von gesamt- salvianolsäure

Country Status (13)

Country Link
US (1) US7641922B2 (de)
EP (1) EP1506951B9 (de)
JP (1) JP4570461B2 (de)
KR (1) KR101004660B1 (de)
CN (1) CN1202103C (de)
AT (1) ATE424379T1 (de)
AU (1) AU2003242135B8 (de)
CA (1) CA2486378C (de)
DE (1) DE60326450D1 (de)
DK (1) DK1506951T3 (de)
ES (1) ES2326165T3 (de)
RU (1) RU2317973C2 (de)
WO (1) WO2003099759A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100339085C (zh) 2003-09-23 2007-09-26 天津天士力制药股份有限公司 治疗心脑血管疾病的中药组合物
CN102579460B (zh) * 2003-12-30 2015-04-29 麦仁斯有限公司 用增强代谢活性的丹参衍生物治疗肥胖和代谢综合症
CN100372525C (zh) * 2004-06-01 2008-03-05 广东天之骄生命科技有限公司 一种复方丹参冻干粉针剂及其制备方法
JP2010180250A (ja) * 2004-07-30 2010-08-19 Iskra Ind Co Ltd 最終糖化産物生成抑制剤
JP4633572B2 (ja) * 2004-07-30 2011-02-16 イスクラ産業株式会社 糖尿病改善剤
JP4868199B2 (ja) * 2004-09-10 2012-02-01 学校法人鈴鹿医療科学大学 サルビアノール酸ｂを有効成分とする神経幹細胞増殖剤
JP2006232698A (ja) * 2005-02-23 2006-09-07 Suzuka Univ Of Medical Science サルビアノール酸ｂ等を主成分とする脳卒中又は脳卒中後遺症の予防用又は治療用薬剤
WO2006115321A1 (en) * 2005-04-25 2006-11-02 Industry Academic Cooperation Foundation, Yeungnam University Composition comprising the extract of salvia miltiorrhiza bge showing enhancing activity for the prevention or treatment of blood circulatory disease.
CN1919251B (zh) * 2005-08-24 2010-11-03 天津天士力制药股份有限公司 治疗心血管疾病的中药组合物
CN1919240B (zh) * 2005-08-24 2011-02-16 天津天士力制药股份有限公司 治疗心脑血管疾病的中药
KR100725839B1 (ko) * 2005-10-06 2007-12-11 일성신약주식회사 단삼으로부터 분리된 탄시논류의 화합물을 함유하는인지기능 장애의 예방 및 치료용 조성물
KR20070040209A (ko) * 2005-10-11 2007-04-16 일성신약주식회사 단삼 분획물을 함유하는 인지기능 장애의 예방 및 치료용 조성물
CN101210002B (zh) * 2006-12-27 2011-04-20 中国科学院大连化学物理研究所 一种丹酚酸b化学对照品的分离制备方法
CN101721468B (zh) * 2008-10-21 2013-02-13 天津天士力之骄药业有限公司 一种丹参总酚酸制备方法
CN101401843B (zh) * 2008-11-18 2011-10-05 阳国平 一种中药丹参有效成分的提取方法
US20120041062A1 (en) * 2009-03-30 2012-02-16 Tianjin Tasly Pharmaceutical Co., Ltd. Compound of salvianolic acid l, preparation method and use thereof
CA2807283C (en) * 2010-08-06 2019-05-14 Xijun Yan Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease
CN104418744B (zh) * 2013-08-29 2017-03-01 天士力制药集团股份有限公司 一种新的丹酚酸化合物t、其制备方法和用途
CN107951981A (zh) * 2017-12-30 2018-04-24 黄旭东 一种筋骨伤涂剂及其制备方法
CN112315997B (zh) * 2020-11-30 2022-03-25 四川省中医药科学院 一种丹参和葛根提取物的固体分散体及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000069296A (ko) * 1996-12-05 2000-11-25 윌리암 제이.하트만 항바이러스 활성을 갖는 살비아 종의 추출물
US6043276A (en) * 1998-06-25 2000-03-28 Georgetown University School Of Medicine Compounds obtained from salvia species having antiviral activity
CN1129572C (zh) * 1998-09-11 2003-12-03 中国科学院上海药物研究所 丹参多酚酸盐混合物及其制备方法和用途
US6299910B1 (en) * 1999-04-07 2001-10-09 Techical Sourcing International, Inc. Methods for identification, purification, and manufacturing of the active constituent in Salvia-miltiorrhiza (dansheng) and the application of this product in enhancing cardiovascular functions
CN1163227C (zh) 1999-04-19 2004-08-25 上海中医药大学 丹酚酸b镁盐在制备治疗慢性肝病药剂中的应用
CN1229324C (zh) 2001-09-26 2005-11-30 中国医学科学院药物研究所 丹参总酚酸的提取方法及其制剂的制法与用途
CN1161317C (zh) 2001-09-27 2004-08-11 华东理工大学 从植物丹参中提取纯化丹参素的方法

Also Published As

Publication number Publication date
ES2326165T3 (es) 2009-10-02
WO2003099759A8 (fr) 2004-03-11
AU2003242135B8 (en) 2009-12-03
CA2486378A1 (en) 2003-12-04
AU2003242135B2 (en) 2009-08-27
CN1459448A (zh) 2003-12-03
WO2003099759A1 (fr) 2003-12-04
KR20050024281A (ko) 2005-03-10
CA2486378C (en) 2011-02-22
DE60326450D1 (de) 2009-04-16
US20050159491A1 (en) 2005-07-21
AU2003242135A1 (en) 2003-12-12
DK1506951T3 (da) 2009-05-25
CN1202103C (zh) 2005-05-18
RU2317973C2 (ru) 2008-02-27
RU2004136577A (ru) 2005-06-27
EP1506951B1 (de) 2009-03-04
EP1506951A1 (de) 2005-02-16
JP4570461B2 (ja) 2010-10-27
JP2005538055A (ja) 2005-12-15
US7641922B2 (en) 2010-01-05
KR101004660B1 (ko) 2011-01-03
EP1506951B9 (de) 2009-08-26
EP1506951A4 (de) 2005-08-03

Similar Documents

Publication Publication Date Title
ATE424379T1 (de) Verfahren zur herstellung von gesamt- salvianolsäure
FR2848117B1 (fr) Procede de preparation d'un extrait de centella asiatica riche en madecassoside et en terminoloside
ATE98219T1 (de) Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte.
ATE495234T1 (de) Verfahren zur herstellung von fettsäurealkylestern aus fettsäureabfall- oder - rezyklatmaterial
DE60300273D1 (de) Verbessertes Verfahren für die Herstellung von Methacrylsäure und Methacrylsäureester
TW200744466A (en) Production process of purified green tea extract
NO794080L (no) Fremgangsmaate for fremstilling av vannfri eller tilnaermet vannfri maursyre.
ATE543793T1 (de) Verfahren zur herstellung von benzoesäureestern
DE60107446D1 (de) Gereinigtes cochinealpigment und verfahren zur herstellung desselben
CN102320953B (zh) 用毛叶山桐子毛油制备天然α-亚麻酸的方法
ATE403478T1 (de) Verfahren zur herstellung von spezifikationsgerechtem phthalsäureanhydrid
EP1405917A3 (de) Verfahren zur Herstellung von 3-Heteroaryl-3-hydroxy-propansäurederivaten durch enantionselektive mikrobielle Reduktion
ATE389625T1 (de) Verfahren zur herstellung von l-idit
WO2000077234A3 (es) Procedimiento de produccion de licopeno
ATE516258T1 (de) Verfahren zur herstellung von monochloressigsäure
CN107473970A (zh) 一种以亚麻籽为原料提取高纯度α‑亚麻酸的方法
DE50105514D1 (de) Verfahren zur Herstellung von Sorbitolen aus Standard-Glucose
DE50106667D1 (de) Verfahren zur Herstellung von optisch und chemisch hochreinen (R)- oder (S)-Hydroxycarbonsäuren
ATE302178T1 (de) Verfahren zur herstellung von spezifikationsgerechtem phthalsäureanhydrid
DE60031133D1 (de) Verfahren zur darstellung von lh-rh-derivaten
DE60314904D1 (de) Verfahren zur herstellung von chinoloncarboxylat-derivaten
WO2001064240A3 (en) Methods for promoting production of myelin by schwann cells
ATE523094T1 (de) Verfahren zur herstellung von perilla frutescens var. crispa f. purpurea-sirup
SU138030A1 (ru) Способ получени поликарбонатов
ATE387432T1 (de) Verfahren zur herstellung von dtpa-bis-anhydrid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1506951

Country of ref document: EP